HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
No edit summary
No edit summary
Line 15: Line 15:
<br />
<br />
{| class="wikitable sortable" style="margin:auto"
{| class="wikitable sortable" style="margin:auto"
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|+<big>cWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|-
|-
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
Line 1,656: Line 1,656:
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
 
 
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
 
 
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
 
 
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX
|ISSUE- FIX


Line 1,673: Line 1,688:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
Line 2,359: Line 2,390:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
!Disease (5th Edition)
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
!Page Type
Zhenya Tang
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|4/14/25||7/14/25
!Date Assigned to Author (5th Edition)
9/4/2025 Sent E-mail reminder to Dr. Tang
!Target Completion Date (5th Edition)
|Pending|| ||SG
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
Zhenya Tang
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
|Pending|| ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
Line 2,413: Line 2,428:
|Prior Date of Last Editor Review (4th Edition)
|Prior Date of Last Editor Review (4th Edition)
|Prior Notes (4th Edition)
|Prior Notes (4th Edition)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|
Line 2,510: Line 2,541:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
!Disease (5th Edition)
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
!Page Type
Michelle Don, MD, MS
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
Michelle Don, MD, MS
|3/17/2024 (trainee name added on 9/9/24 by JH)
|3/17/2024 (trainee name added on 9/9/24 by JH)
|6/30/24
|6/30/24
Line 2,580: Line 2,595:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
Line 2,635: Line 2,666:
|
|
|-
|-
!Disease (5th Edition)
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
!Page Type
|3/19/2024
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|3/19/2024
| ||Pending
| ||Pending
| ||SK|| ||
| ||SK|| ||
Line 2,689: Line 2,704:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
Line 2,745: Line 2,776:
|
|
|-
|-
!Disease (5th Edition)
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
!Page Type
 
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
 
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||Pending
Line 2,794: Line 2,809:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
Line 2,854: Line 2,885:
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
Line 2,895: Line 2,910:
|11/21/2021
|11/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|
|